MDWD · MediWound Ltd. · Investor Relations

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid ® Award raises the total program budget to $21.8 million and supports development through Investigational New Drug (IND) submission for battlefield burn care YAVNE,

Independent DSMB Recommends MediWound’s EscharEx ® Phase III VALUE Study Continue Without Modification DSMB did not identify safety concerns in pre-specified review; interim assessment and enrollment completion remain on track for end of the first quarter of 2027 YAVNE, Israel, September 14, 2026

MediWound to Present at the H.C. Wainwright 28 th Annual Global Investment Conference YAVNE, Israel, September 2, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will

EscharEx ® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under its BARDA Contract for NexoBrid ® Second Quarter Revenue of $3.1 Million; Full-Year 2026 Revenue Guidance of $24–26

MediWound to Report Second Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Thursday, August 13 at 8:30 a.m. Eastern Time YAVNE, Israel, July 29, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today

EscharEx ® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027 First quarter revenue of $1.5 million; full-year 2026 revenue guidance reaffirmed at $24-26 million Conference Call Today, May 27, 2026, at 8:30 a.m.

MediWound to Report First Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Wednesday, May 27 th at 8:30 a.m. Eastern Time YAVNE, Israel, May 7, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced

Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement Peer-reviewed consensus redefines debridement from simple tissue removal to a more comprehensive biologically active driver of wound healing Panel supports early use of effective, less invasive

MediWound to Present New EscharEx ® Data at Leading Wound Care Conferences Data highlights mechanism of action, outcomes in VLUs and DFUs, and comparative advantages over SANTYL ® Findings support ongoing VALUE Phase III study and planned expansion into DFUs and pressure ulcers YAVNE, Israel,

MediWound Reports BARDA Contract Award to Vericel for NexoBrid ® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair, today announced that Vericel Corporation

MediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5, 202 6 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, t oday announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with